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Abstract
Background: Complete resection seemed to be curative in patients with Castleman disease of
any location but the disease is likely to be reactive in its pathogenesis. The relation between
Epstein-Barr virus and Castleman disease has not been elucidated. We tried to define the role of
Epstein-Barr virus in the pathogenesis of Castleman disease.
Methods: 20 cases of Castleman disease were retrospectively reviewed from 1993 to 2006. At
least 2 to 4 representative sections of formalin-fixed, paraffin-embedded specimens from each
patient were obtained to examine the presence of EBV and its localization by hematoxylin-eosin
stain, immunohistochemistry, polymerase chain reaction and In-situ hybridization
Results: Hyaline-vascular type was diagnosed in 18 cases, plasma cell type in 1 and mixed type in
1 case. All of them were positive for Epstein-Barr virus confirmed by PCR. For tumors that
EBER(Epstein-Barr early region) signals mainly localized in the germinal centers have increased
vascularity than cases with EBER detected in inter-follicular areas.
Conclusion: There is a strong association between Castleman disease and Epstein-Barr virus. EBV
may have a potential role in angiogenesis of Castleman disease. For smaller lesion with high activity
of angiogenesis but not amenable for curative resection, anti-angiogenesis medications may have a
potential role to control the disease.
Background
Castleman disease (CD) is a rare and usually benign lym-
phproliferative disease. It has many synonyms, including
giant lymph node hyperplasia, angiofollicular hyperpla-
sia, lymph node harmatoma, benign giant lymphoma,
and follicular lymphoreticuloma. Castleman et al first
described it as a new disease entity in 1956[1]. Subse-
quently in 1972, Keller defined Castleman disease both
clinically and histologically.[2] It has 2 clinical types, uni-
centric and multicentric and 3 histologic types, hyaline-
vascular type, plasma cell type and mixed type. Because it
is rare, the essence of the disease remained unclear in
many aspects, including etiology, pathogenesis and long-
term outcome. Some studies have suggested that some
kinds of virus may be implicated in the pathogenesis of
CD. Jones et al published 5 cases studied by immunohis-
tochemistry, which indicated there might be possible
roles for EBV or cytomegalovirus(CMV) in the pathogen-
esis of CD but this deduction was not supported by subse-
quent studies[3,4]. In recent years, abnormal lymphoid
follicles in CD became the focus of study. Production of
Interleukin-6 (IL-6) in abnormal lymphoid follicles of CD
was thought to be related to its pathogenesis because aber-
rant production of IL-6 was not identified in normal lym-
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phoid tissues[5]. In the experiences of lymphoma, EBV-
mediated IL-6 acts as an autocrine growth factor in some
EBV infected lymphocytes and in nasopharyngeal carci-
noma, EBV-mediated Interleukin-8 may promote angio-
genesis[6,7]. Based on these facts, we wonder if EBV has
any potential role in the pathogenesis of CD and in extent
of vascularity.
Materials and methods
From January, 1994 to December, 2005, we retrospec-
tively reviewed 20 cases with the diagnosis of Castleman
disease managed in Mackay Memorial hospital in Taiwan.
We retrieved all formalin-fixed, paraffin-embedded speci-
mens of these cases from Pathology specimen bank. The
diagnosis of these cases was confirmed both clinically and
histologically using the criteria described by Keller in
1972[2]. After excluding one specimen that is too small
for extraction of sufficient DNA, there are 19 cases
included in our study.
For each case, we selected at least 2 to 4 representative for-
malin-fixed, paraffin embedded specimens. For each spec-
imen, 7 to 8 sections of 5 to 10 μm thickness were
obtained for crude extracts of subsequent study. One sec-
tion of each specimen was stained by Hematoxylin-Eosin,
one for immunohistochemistry stain while another one
section was for In-situ hybridization. Immunohistochem-
istry was performed in selected cases. After dissolving in
xylene, DNA was then extracted from tissues of the
remaining 4 sections by alcohol-phenol extraction
method (QIAamp DNA Mini Kit).
For hyaline-vascular type and mixed type, we divided
these cases into highly vascular and less vascular accord-
ing to HE stain. If more than 50% follicles were sur-
rounded by proliferated vessels, these cases are defined as
hypervascular cases. If less than 50% follicles are sur-
rounded by the proliferated vessels, these cases were
defined as less vascular cases.
For confirming the acceptability of the DNA as amplifica-
tion template after extraction, we used polymerase chain
reaction (PCR) assay by one primer pair designed to
amplify the genes corresponding to β-globin region of
human genomic DNA[8]. The expected length of ampli-
fied target segment is 110 base pairs. The details of the
sequences of the primers and amplification program are
listed in table 1. The total volume of reaction mixture is 50
μl. One fifth of the PCR product was subjected to electro-
phoresis on a 2% agarose gel.
For detection of EBV in our specimens, we selected 2 target
genes for amplification by PCR. They are EBER (EB early
region) and EBNA-2 (EB nuclear antigen)[9,10] Primer
design and amplification programs are listed in Table 1.
Positive control is DNA extraction from tissues from a case
with the diagnosis of nasopharyngeal carcinoma previ-
ously confirmed to be EBV-positive. Distilled water was
used as negative control.
Because of high copy number of EBER during latent EBV
infection, we selected EBER as the target for In-situ hybrid-
ization, a method previously described[11]. The positive
control is also the tissues of nasopharyngeal carcinoma
previously confirmed to be EBV-positive. The distribu-
tions of EBER signals within each specimen are classified
into germinal center (GC-EBV) or inter-follicular (IF-EBV)
localizations according to direct observation under fluo-
rescent microscopy. Localization of EBER signals in germi-
nal centers (GC-EBV) is defined if these signals were
confined within germinal centers or if quantity of EBER
signals within germinal centers are obviously more than
those in the inter-follicular space. If the signals were
mainly detected in inter-follicular space, they were desig-
nated as IF-EBV.
Chi-square test and Student T-test were used to compare
the characteristics of both groups. A P-value less than 0.05
is considered as significant.
Results
There are 19 cases included in this study with 17 hyaline-
vascular CD, 1 plasma cell type and 1 mixed type. The
only one plasma cell type is also a multicentric type while
the remaining 18 cases are of unicentric type. There are 10
males and 9 females with mean age of 30.7 years (range:
Table 1: Primers Design, Sequences and Amplification programs for Polymerase Chain Reaction
Target Sequence (5' to 3') 1 2 3 4 5 6
β-globin
PC03 ACACAACTGTGTTCACTAGC 94°C 94°C 55°C 72°C 72°C 4°C
PC04 CAACTTCATCCACGTTCACC 5 min 30 sec 40 sec 1 min 8 min 2~4 35 cycle
EBV
EBNA-2(F) AGGCTGCCCACCCTGAGGAT 94°C 94°C 56°C 72°C 72°C 4°C
EBNA-2(R) GCCACCTGGCAGCCCTAAAG 5 min 1 min 1 min 1 min 10 min 2~4 35 cycle
EBER(F) GTGGTCCGCATGTTTTGATC 94°C 94°C 58°C 72°C 72°C 4°C
EBER(R) GCAACGGCTGTCCTGTTTGA 5 min 30 sec 1 min 2 min 10 min 2~4 35 cycle
EBV: Epstein-Barr virus, EBNA: Epstein-Barr Nuclear Antigen, F: forward, R: reverseJournal of Cardiothoracic Surgery 2009, 4:31 http://www.cardiothoracicsurgery.org/content/4/1/31
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9 to 68). There are 8 patients having CD in the thorax, 5
in the neck, 2 in the retroperitoneum and 4 in other loca-
tions (axilla, inguina, retropertoneum, etc). All specimens
were found to be EBV-positive by PCR amplification of
both EBER and EBNA-2. 10 specimens were classified as
hypervascular CD and 8 specimens were classified as less
vascular CD. The demographics, results of EBV detection
and localization and extent of vascularity of each case are
listed in table 2.
We excluded one case of plasma cell type when we com-
pare the localization of EBV and the extent of vascularity
because it lacks vascular component. We divided these
cases into 2 groups, with one that EBER signals were
mainly localized in the germinal centers and another one
having signals mainly in inter-follicular areas. There are
12 cases having EBER signal in areas of germinal centers
and 6 cases having signals in inter-follicular areas. In the
group of EBV localized within germinal centers (GC-EBV),
patients tend to be older (p = 0.064, not statistically sig-
nificant), the size of the tumor is smaller (p = 0.003) and
more likely to be highly vascular (p = 0.01). There is bor-
derline significance that females tend to have EBV in the
follicular space.(p = 0.046) However, there is no signifi-
cant difference in the locations of CD. The results of com-
parison are listed in Table 3.
Discussion
Epstein-Barr virus is a lymphotropic herpesvirus and its
infection rate varies geographically. Usually, the clinical
course after infection by EBV is indolent. However, there
are strong associations between EBV and infectious
mononucleosis, nasopharyngeal carcinoma, Hodgkin's
disease and Burkett's lymphoma[12]. In addition, EBV
was highly associated with posttransplant lymphoma and
other lymphoproliferative disorder, especially in immu-
nocompromised state[13,14].
There are many strategies to detect the presence of EBV in
formalin-fixed, paraffin-embedded specimen. The role of
polymerase chain reaction in detection of EBV in paraffin-
embedded specimen is quite limited because EBV is ubiq-
uitous. Without the information of its localization, inter-
pretation of positive result becomes difficult and is often
meaningless. In-situ hybridization provided additional
information about the localization of EBV and may help
us to clarify its relationship with 2-dimensional structures
within pathologic lymph node. Gene expressions of EBV
during latent phase are so limited that detection is diffi-
cult. EBERs, however, are polymerase III transcripts and
abundantly expressed in EBV-infected cells, up to 107 cop-
ies per infected cell during latency, which makes them
excellent targets for detection[15].
Interleukin-6 production in abnormal lymphoid follicles
by germinal center cells was identified by both IHC stain
and ISH in previous studies[5,16]. In animal study, IL-6
also produced Castleman-like syndrome[17]. In EBV-pos-
itive cells, IL-6 may act as an autocrine growth factor for
lymphocytes[6]. Reasonably, EBV located within germinal
Table 2: Demographics and Results of EBV Detection
Cases Age (year) Gender Location Histologic type Greatest diameter of 
lesion (cm)
EBV PCR EBNA-2/
EBER
EBV ISH Vascularity
1 25 M left neck HV 5 +/+ IF L
2 21 M left neck HV 5 +/+ IF L
3 26 F left neck HV 5 +/+ GC L
42 4 M m e d i a s t i n u m H V 6 + / + I F L
53 9 F m e d i a s t i n u m H V 1 . 5 + / + G C L
61 7 M m e d i a s t i n u m H V 5 . 7 + / + I F L
7 33 F retroperitoneum mixed 8 +/+ IF L
82 6 M L e f t  n e c k H V 2 + / + G C H
9 9 F left neck HV 5.5 +/+ GC H
10 52 M Left axilla HV 1.5 +/+ GC H
11 19 F Left neck HV 3 +/+ GC H
12 52 F left axilla HV 2 +/+ GC H
13 68 M right axilla HV 3 +/+ GC H
14 50 M left neck HV 3 +/+ GC H
15 33 F mesocolic lymph node HV 5 +/+ GC H
16 32 F retroperitoneum HV 5.6 +/+ GC H
17 19 M mediastinum HV 7 +/+ IF L
18 39 F mediastinum HV 5 +/+ GC H
19 53 M bil axilla, bil inguinal PC 4 +/+ IF -
M: male; F; female; HV: hyaline-vascular type; PC: plasma cell type; EBV PCR: results of polymerase chain reaction, + stands for positive; EBV ISH: 
localization of Epstein-Barr virus detected by in-situ hybridization, GC means signals within germinal centers, IF represents signals detected in inter-
follicular space; H and L indicate highly vascular and less vascular CD.Journal of Cardiothoracic Surgery 2009, 4:31 http://www.cardiothoracicsurgery.org/content/4/1/31
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centers may promote production of IL-6, subsequently
leading to the development of Castleman disease.
Murray et al published their experience of 15 cases of Cas-
tleman disease studied by IHC stain and in situ hybridiza-
tion. They demonstrated that only 6 out of 15 cases were
found to have scanty EBV-positive cells. And these EBV-
positive lymphocytes are few, confined to the inter-follic-
ular areas and never seen in germinal centers. Thus, they
concluded that EBV is not associated with Castleman dis-
ease. In this study, the results of our observation are
greatly different. EBV-positive cells were abundantly
found in 19(100%) cases by both PCR and ISH. 12 out of
19 cases were found to have rich EBV-positive cells in ger-
minal centers while remaining 7 cases in the inter-follicu-
lar areas. We also observed that more EBV-positive cells in
germinal centers accompanied with more vascular prolif-
erations in these tumors, suggesting that localization of
EBV in germinal centers may relate or contribute to some
extent of vascular proliferation in hyaline-vascular CD.
EBV may promote angiogenesis through expression of
Latent Membrane protein-1 (LMP-1) induced production
of Interleukin-8, as in the case of nasopharyngeal carci-
noma[7]. Although such relationship was not established
in CD, it may explain the results of our observation.
Tumor size measured by greatest dimension in IF-EBV
group is significantly larger than that in GC-EBV group. (P
= 0.003) There are at least 2 possibilities to explain this
finding. First, localization of EBV may be a dynamic proc-
ess. During disease progression, these EBV-infected lym-
phocytes shifted from predominantly intra-follicular
areas where they promote angiogenesis and initialize
tumor enlargement, to inter-follicular areas during the
course of tumor enlargement and disease progression. The
marked difference in tumor size we observed may repre-
sent different stages of the 2 groups during tumor enlarge-
ment and disease progression. And different stages have
its corresponding distribution of EBV. Second, localiza-
tion of EBV in inter-follicular areas may lead to larger
tumor size with decreased angiogenesis through
unknown mechanism. Differentiation of the 2 possibili-
ties requires further investigations to define the role of
EBV in CD.
For surgeons, complete resection is not possible in every
case. Knowing the underlying pathogenesis may reveal
potential alternative or adjuvant treatment when com-
plete resection is not possible or a patient could not toler-
ate major resection. Most lesions that could not be
completely resected are those deep in the thoracic cavity.
The new findings may help thoracic surgeons to consider
the applications of either alternative or adjuvant therapy.
Since many medications and even radiation therapy could
block angiogenesis. This may explaine why some reports
showed radiation and chemotherapy can control but not
cure the disease[18].
One limitation of this study is lack of non-CD tissues in
each case because no or only scanty non-tumor tissues
were preserved in our Pathology specimen bank. Near all
formalin-fixed, paraffin-embedded tissues we obtained
contain only pathologic lymph nodes, which limited us to
evaluate the role of EBV in both tumor parts and non-
tumor parts of each patient.
Conclusion
Epstein-Barr virus is highly associated with Castleman dis-
ease. More EBV-positive cells in germinal centers are asso-
ciated with increased vascularity and smaller tumor size.
EBV may play a role of angiogenesis in early stage of Cas-
tleman Disease. For lesions with high activity of angiogen-
esis but not amenable for curative resection, strategy for
anti-angiogenesis may have a potential role to control the
disease.
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Table 3: Comparison of characteristics of CD with different 
distributions of EBV.
GC-EBV IF-EBV P-value
N = 12 N = 6
Age(years) 37.1 23.2 0.064
Male/Female 5/7 5/1 0.046*
Location of CD N.S.
Neck 6 2
Mediastinum 2 3
Axilla 2 0
others 2 1
Greatest Diameter (cm) 3.5 6.1 0.003*
Vascularity 0.010*
High 10 0
Low 2 6
CD: Castleman disease, GC-EBV: EBV was mainly detected in 
germinal centers, IF-EBV: EBV was detected mainly in inter-follicular 
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